Research finds niacin reduces miR-93 and improves liver fat metabolism in mice — Evidence Review
Published in Metabolism, by researchers from UNIST, Pusan National University, Ulsan University Hospital
Researched by
— the AI search engine for science
Table of Contents
A new study identifies the small RNA molecule miR-93 as a key driver in fatty liver disease and suggests that niacin (vitamin B3) can reverse its effects in mice. Related research generally supports the therapeutic potential of niacin for fatty liver disease through multiple mechanisms.
- Multiple animal and human studies have shown that niacin reduces liver fat accumulation, oxidative stress, and inflammation in nonalcoholic fatty liver disease, lending support to the new study’s findings that niacin improves liver health by targeting molecular pathways involved in fat metabolism 1 2 3 4 5.
- While some previous research focused on different mechanisms (e.g., inhibition of diacylglycerol acyltransferase 2 or activation of GPR109A/AMPK pathways), the new study adds insight by linking niacin’s effect to the miR-93/SIRT1 axis, broadening understanding of how niacin may benefit metabolic liver disease 1 2 4.
- Other vitamins, such as vitamin E, have also shown beneficial effects in nonalcoholic fatty liver disease, but vitamin D’s impact remains uncertain, highlighting that not all vitamins have consistent evidence for efficacy in liver disease 8 9 10 12.
Study Overview and Key Findings
Metabolic-associated fatty liver disease (MASLD) affects a significant portion of the global population and is closely linked to rising rates of obesity and type 2 diabetes. Despite its prevalence, effective pharmacological treatments are limited, making research into its molecular drivers and possible interventions particularly timely. This study stands out by identifying a novel microRNA (miR-93) as a central node in fat metabolism disruption within the liver, and by proposing the repurposing of a common vitamin—niacin—as a potential therapeutic tool, offering new avenues for intervention in a disease with few current options.
| Property | Value |
|---|---|
| Study Year | 2025 |
| Organization | UNIST, Pusan National University, Ulsan University Hospital |
| Journal Name | Metabolism |
| Authors | Yo Han Lee, Jinyoung Lee, Joonho Jeong, Kieun Park, Bukyung Baik, Yuseong Kwon, Kimyeong Kim, Keon Woo Khim, Haneul Ji, Ji Young Lee, Kwangho Kim, Ji Won Kim, Tam Dao, Misung Kim, Tae Young Lee, Yong Ryoul Yang, Haejin Yoon, Dongryeol Ryu, Seonghwan Hwang, Haeseung Lee, Jang Hyun Choi |
| Population | Mice with metabolic-associated fatty liver disease |
| Methods | Animal Study |
| Outcome | miR-93 levels, SIRT1 activity, liver fat accumulation |
| Results | Niacin reduced miR-93 and improved liver fat metabolism in mice. |
Literature Review: Related Studies
We searched the Consensus paper database, which contains over 200 million research papers, to identify relevant studies on niacin, miR-93, and vitamin effects in liver health. The following search queries were used:
- niacin fatty liver disease treatment
- miR-93 liver fat metabolism mice
- vitamin effects on liver health
Related Studies Table
| Topic | Key Findings |
|---|---|
| How effective is niacin in reducing liver fat and improving fatty liver disease? | - Niacin inhibits fat accumulation and oxidative stress in hepatocytes and regresses steatosis in animal models 1 2 4. - Niacin reduces liver fat content in human studies, with genetic factors (e.g., DGAT2 polymorphisms) influencing response 3 5. |
| What is the role of miR-93 and SIRT1 in liver fat metabolism and disease? | - miR-93 modulates genes involved in fat metabolism, including sirtuins, and its dysregulation can influence adiposity and liver steatosis 6 7. - Suppression of SIRT1 by miR-93 leads to disrupted metabolic pathways and increased fat storage in the liver 7. |
| How do other vitamins (E, D) compare in the management of fatty liver disease? | - Vitamin E supplementation improves liver function and histological outcomes in nonalcoholic fatty liver disease (NAFLD), with evidence from meta-analyses and cohort studies 8 9 12. - Vitamin D supplementation shows inconsistent effects on liver outcomes, with meta-analyses indicating very low-quality evidence and no clear benefit 10 11. |
How effective is niacin in reducing liver fat and improving fatty liver disease?
A substantial body of research supports niacin’s beneficial effects in experimental models and some human studies of fatty liver disease. These studies consistently show that niacin reduces hepatic fat accumulation, oxidative stress, and inflammation, and can reverse or prevent steatosis. The mechanisms proposed include inhibition of triglyceride synthesis enzymes and activation of specific signaling pathways. The new study builds upon this evidence by highlighting a novel miR-93/SIRT1 pathway as an additional target for niacin’s action.
- Niacin decreases liver fat, oxidative products, and inflammation in both in vitro and in vivo models of fatty liver disease 1 2 4.
- Multiple animal studies found that niacin leads to regression or prevention of steatosis and improves hepatic biomarkers 2 4.
- Human trials have demonstrated reductions in liver fat content with niacin therapy, though genetic variants in DGAT2 may influence the degree of benefit 3 5.
- The new study offers mechanistic insights by showing that niacin downregulates miR-93 and restores SIRT1 activity, expanding the understanding of how niacin may influence liver metabolism 7.
What is the role of miR-93 and SIRT1 in liver fat metabolism and disease?
Emerging studies indicate that microRNAs, such as miR-93, play significant regulatory roles in fat metabolism and energy balance. miR-93 has been shown to target sirtuins (notably SIRT1 and SIRT7), which are key regulators of fatty acid oxidation and metabolic stress responses. The suppression of SIRT1 by miR-93, as demonstrated in the new study, disrupts these metabolic pathways, promoting fat accumulation and impaired energy homeostasis in the liver.
- miR-93 inhibits sirtuin family members (SIRT1, SIRT7), leading to increased fat deposition and metabolic dysfunction 6 7.
- In mouse models, miR-93 deficiency upregulates genes involved in fatty acid oxidation and downregulates those associated with cholesterol biosynthesis, reducing liver steatosis 7.
- The new study directly links miR-93 elevation to SIRT1 suppression and identifies niacin as an agent capable of reversing this effect 7.
- While earlier studies emphasized miR-93’s role in adipogenesis and insulin resistance, the new findings extend its significance to liver-specific metabolic disease 6.
How do other vitamins (E, D) compare in the management of fatty liver disease?
The therapeutic landscape for fatty liver disease has included trials of various vitamin supplements. Vitamin E is supported by several randomized trials and meta-analyses as beneficial for improving liver enzymes, histological features, and clinical outcomes in nonalcoholic fatty liver disease and steatohepatitis. In contrast, vitamin D supplementation has not demonstrated clear or consistent benefit in chronic liver diseases, according to systematic reviews and meta-analyses.
- Vitamin E supplementation is associated with improvements in liver function, histology, and transplant-free survival in NAFLD and NASH patients 8 9 12.
- Meta-analyses report that vitamin E reduces markers of liver injury and can help resolve histopathological features of fatty liver disease 8 12.
- Vitamin D supplementation does not show reliable benefit for liver-related or overall mortality, according to evidence from randomized trials and meta-analyses; the overall quality of evidence is low 10.
- Observational and experimental studies suggest vitamin D status may be linked to NAFLD severity, but interventional data remain inconclusive 11.
Future Research Questions
Despite promising preclinical findings, several important questions remain regarding the translation of these results to clinical practice, the long-term safety and efficacy of niacin, and the broader applicability of targeting miR-93 in metabolic liver diseases. Future research should address these gaps and clarify the mechanisms and outcomes in diverse populations.
| Research Question | Relevance |
|---|---|
| Does niacin reduce liver fat and improve outcomes in humans with metabolic-associated fatty liver disease? | While animal studies and small human trials suggest benefit, large-scale clinical trials are needed to confirm niacin’s efficacy and safety in human MASLD patients 2 3 4 5. |
| What are the long-term effects and safety profile of niacin treatment in liver disease patients? | Niacin can cause side effects at high doses, and its long-term safety in liver disease populations remains unclear; this is critical for evaluating its use as a chronic therapy 3 4. |
| Does modulating miR-93 impact other metabolic pathways beyond SIRT1 in humans? | The specificity and broader metabolic consequences of targeting miR-93 need investigation to ensure unintended effects are minimized 6 7. |
| How do genetic polymorphisms (e.g. DGAT2) influence response to niacin therapy in fatty liver disease? | Genetic variability may affect how patients respond to niacin, as shown in previous human studies, making personalized approaches an important area for future research 3. |
| Can combination therapies targeting miRNA pathways and conventional agents enhance treatment efficacy in MASLD? | Exploring combination treatments could offer synergistic benefits and overcome limitations of single-agent therapies, as suggested by the potential for niacin to be used with other modalities 7. |